Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would prefer warrants at .20 cents are exercises first and do a raise higher.
will be a raise.
but we need it. do we not?
Have you been around for the last 5 raises?
It is plain to see from this volume alone that there are a lot of folks excited to scoop up more shares at a discount. This stock is heading higher shortly. I do not think a raise is coming today or even this week, especially if warrants are getting exercised, but what do I know... I don't think we are desperate for money quite yet and Mac and team will hopefully let this ride higher before doing a raise, and announce continued positive news to keep the momentum going.
People need to understand a stock cannot go straight up everyday. We have a lot of shares recently issued down here to churn through, which we have been doing, especially for those new investors with warrants who may have already sold their shares and are hanging on to warrants for now to see how things progress. A down day like this will not steal my smile and excitement for our future.
too many* feeling is all too familiar.
Worst part is we know the pain is coming but i wont sell my shares to retain LT tax holding.... however given recent PR's, this is the best ive felt about adding after a capital raise
Its just gotta be another raise. Those of us that have been here for over 5 years have seen this so many times...
The Caribbean certainly has it's allure... By the time we are ready, they should have everything fixed up again. Vegas also has a little healing to do right now, but they also should be back in better moods when it's party time for us.
I expect an occasional dip as well, whether for profit taking, or in advance of a raise (would be nice to know like so many others seem to know... leaks!) but it shouldn't have to be double-digit drops when it happens. As long as we continue to have more up days then down, or at least bigger climbs on the ups to maintain the positive trend, we will do just fine.
I am also very suspicious when I see small $20-100 transactions that make PPS reverse direction.
why not wait until this drops another 20% after they announce the raise?
Mama said there'd be days like this. We knew we'd see dips. So this shouldn't alarm anyone or send them into a sky is falling mindset. BigT can probably answer it better but it could be the MM's playing games or a lot of those who bought in at .10/.11 are taking some profits. But I think we'll be just fine. Just a dip in the road.
I'm on the brink of buying more.
At this point, I am so far in, that a couple more G's won't even matter. My chances of making my money back now are higher, considering such a low PPS. I really expected this to go higher, considering all the movement we've had lately. Anyone else hella depressed thinking of the day we all meet in the Caribbean when we make a killing off of this?
Getting ugly.....so much for my good feeling.
There has been a big gap between bid and ask all day today. Looks like the MMs are having their way with us.
Agreed - i too think it will be today
Seems too soon for a raise but the market is acting like it is. I'm thinking it's just a bit of pullback from a nice run amplified in a downward flinch by those among us who suffer from "battered Titan long syndrome" in expectation of the smack of a backhand raise. If that's the case we might get a bounce once people are convinced the raise isn't happening and there's no reason for the drop.
Based on volume and pps today, I would guess the announcement will come after hours today. Classic positive news followed by more dilution. Announcement will be for Canadian shareholders only. Rinse and repeat.
Im guessing within the week. We've seen the run up on news, follwoed by sharp down days right before announcement. Maybe this week?
So under this theory are we in the second ABCD pattern since we started to takeoff? Are we in the B pattern following an A which started around 9/27 at ~.20 pps? If so, the next C to follow should push us over the .30 mark, correct?
When? Today? Tomorrow?
Next month?
The raise is coming, we all knew we needed cash in the short term and the market always knows before us....
My business partner has access to a couple of there executives. He says there very careful about what they divulge, and a lot of what is discussed is public (timelines).
why would he tell.
relax and make your own calls
How do you know all of this? What is your source?
WSJ ideas... Just a few bullet points that may be worth mentioning if you correspond with either of the previously provided email addresses (I'll paste them in below again for convenience).
Playing the "Why aren't you covering this?" card:
- Tell them you are a stockholder or are interested in their stock but don't seem to be getting any information from WSJ.
-You have been reading about recent events from the management change to milestone achievements to training site placements
- Early reviews by the surgeons who used it are rave reviews about this groundbreaking new technology
- Mention some specific benefits, e.g. one incision instead of four or five, better dexterity, surgeon comfort, enhanced 3D visibility, smaller packaging, lower price and costs...
- Let them know you are getting disappointed that they haven't provided any coverage while others are.
Playing the "I heard stuff, can you please provide more info or coverage?" card:
- Your profession can tie into how/why/where you have heard/became aware of Titan
- You have been looking around the web and see glowing reviews from recent events being talked about, maybe specify one or two newsworthy announcements to mention to them
- You are looking for guidance and background on Titan and you typically turn to the WSJ as a trusted source of information for investment choices or technological updates (if you are in medicine)
- You might express some disappointment that you haven't seen anything from them yet about Titan
- Outright ask them if they are aware of Titan Medical and if they plan to provide any coverage of the story as it is unfolding; maybe mention that others are starting to pick up the story.
For either option:
- Feel free to provide your own background. Telling them how your professional career ties in will give your request more credibility.
- If you are a subscriber, point that out as well!
- Put everything in your own words; maybe try to purposefully not use some of my words, lest we look like we are starting some sort of a coordinated campaign to get them on board (we don't want to look like we are begging!)
- Pick a couple/few of the above points as they pertain to you and your interests, and can maybe expound upon them a little more in your email.
Feel free to post your letters here as well, if you wish to share!
Christopher.mims@wsj.com
Science & Tech Columnist - I'll probably write to him because of my technical background
Dennis.Berman@wsj.com
Business including Health Sector - if you are more medical or investment oriented, he might be a better recipient for you.
A couple of things:
Warrants HAVE been getting exercised recently. Not sure how much, but Titan is encouraging those to exercise. This has been helpful in that it is giving them a little more time and flexibility as far as future financing. I don't believe todays pullback is finance related (could be wrong), but not the impression I got. Just seems like big resistance at .28.
R/S will NOT happen in 2017, subsequently no Nasdaq uplist in 2017. Both slated for 2018. The only way this could change is if the PPS shot up to ridiculous levels short term. They prefer to R/S when the PPS is much higher and they have positive news, updates, etc to support the R/S. This was reiterated again about supporting the PPS after a R/S. They are VERY aware of potential pullback, and want to be prepared to support the PPS. They would much prefer to do a smaller R/S at 5/1, 10/1 instead of 30/1.
FDA/CE submission not until the end of 2018. As we know they had been in contact with the FDA a while back. It sounds like they haven't been lately, but they will begin talking again soon to make sure no surprises and get up to date on everything.
Next Quarterly meeting/update is roughly scheduled for mid-November.
Burn rate is still around 2mil a month and should remain so until end of the year. 2018 it will bump up to around 2.5-3mil a month through the year.
Partnerships are an ongoing possibility. No details, but they are always talking, entertaining, etc, etc. They consider the big boys in Medical (Medtronic, J & J, etc) as prospects for future partnerships, buyouts, etc. They really feel single port is the future and these guys know it.
The team is "highly energized" and excited right now.
Lastly, McNally and Randall were in Europe last week. Thoughts, conspiracy theories???
GLTA
It's a healthy dip...already passed the worst it looks like.
ABCD patterns are the best for pps increase. Not sustainable otherwise.
Florida Hospital Nicholson Center
Our world-renowned @Florida Hospital physicians, Vipul Patel, MD and Eduardo Parra-Davila, MD tested out the feasibility of @Titan Medical Inc's SPORT System through single port abdominal robotic surgery last week at our facility. Both physicians found this system to be a valuable tool in their surgical disciplines. Read more: https://lnkd.in/eGhnR4m
Too bad the market doesn't think the same
Florida Hospital is talking up SPORT on LinkedIn again this morning, this time saying their surgeons find SPORT to be surgically valuable...
Smart money always knows whats to come - next raise announcement tomorrow?
most basises are high for the longs so you will never catch it all at the bottom.
buying at .27 is still lower than .50.
safer play buying some now and then drips and drabs if it goes lower. offering may come at a price when the stock is at .35 and only pull back to .25
I'm just waiting for the next offering and I'm loading up one last time !
Think of Titan as a prostitute
She always goes down and she is happy to take your money and put you at RISK!!!
Lol... Going down
Wall Street Journal Time! Looking forward to 66's ideas! Now especially is the time!!!!
As mentioned previously, a pullback is to be expected after a multi week run. This dip will get bought eventually, and gives those of us who want to add another opportunity at a discount. This again will shake out the weak hands who are not long term investors and have a small gain from their purchase last week.
This was just posted at 9:30am Eastern time from Nicholson Center on their Facebook feed.
Our world-renowned Global Robotics Institute Florida Hospital Celebration Health physicians, Vipul Patel, MD and Eduardo Parra-Davila, MD tested out the feasibility of Titan Medical's SPORT System through single port abdominal robotic surgery last week at our facility. Both physicians found this system to be a valuable tool in their surgical disciplines. Read more: https://hubs.ly/H08P9Vv0
Agreed GLG it looked like very sloppy seller at first but guy hasnt let up .......sure acts like offering in the works from past experience
thoughts on a short or a raise coming
Mine too.
Let's go.
I'm back online now too
Certainly seems that way...
Nothing on marketwired
Guess not never mind
Let's Get to Point Five Eight !!!!
Sadly my break even
Completely Agree! Well said and I love the approach.
I'm in! We will need a couple different approaches, some asking why they aren't covering it, and others asking WSJ for info about them (as if we didn't know). I'll start putting together some outlines today if I get a chance.
Gonna be a great day at TITXF!
I can feel it baby!!
$$TITXF$$$
SPORT=GAME CHANGER
That was me calling out the 200DMA (ie: a technical standard indicator).. I would say doubling from here isn't hard, just takes time...
Christopher.mims@wsj.com
Science & Tech Columnist (could be worth a shot to target a non-business journalist so the OTC business side dosen't factor in and the "game-changing" tech is just focused on. (Surgeon testimonials, Dr. Estape, Nicholson, Columbia, multiple indications, single port is the future, etc.)
Dennis.K.Berman (Dennis.Berman@wsj.com)
Business including Health Sector
Renavatio mentioned that Titan's one institutional investor was in fact a HEAVY HITTER on Wall Street and he is backing Titan.
66 mustang, thoughts? Anyone else feel like grassrootin us into the Wall Street Journal. Especially since we are coming to Columbia NYC!!
Sorry buddy but I disagree. You will need a commercial sales team ready at least 6 months prior to FDA, 3 months at a minimum. A small group should be hired 12 months prior minimum.
The strategy you describe will support a couple of systems, but will not be robust to sustain a successful launch across the US, and will only bring in deals that are already convinced Sport is the right platform.
No need for a rep in all 50 states though, but around 10-15 to begin with.
Titan Medical
January 10, 2022 Titan Medical Corporate Presentation
https://d1io3yog0oux5.cloudfront.net/_101e2d94c73b26bc133246c537736f29/titanmedicalinc/db/1086/9873/pdf/Titan+-+IR+Presentation+-+Q1+2022+FINAL.pdf
*200+ patents issued or pending
Surgeon Feedback From Initial Clinical Testing:
Ricardo Estape, M.D., a robotic gynecologic oncology surgeon from South Miami Gynecology Oncology Group who specializes in robotic single port surgeries, said, “The SPORT Surgical System performed beyond my expectations and I was able to complete a variety of critical surgical tasks with the necessary dexterity and precision through a single incision. The robotic instruments provided the necessary articulation, range of motion and rigidity along with 3D high-definition video on the flat panel monitor that allowed me to complete the surgery in a comfortable posture. This could be a game changer in gynecological surgery.” SEE VIDEO
Eduardo Parra-Davila, M.D., a robotic colorectal surgeon at Florida Hospital who has trained thousands of surgeons worldwide on robotic surgery, commented, “Single port surgery without robotic assistance is not easy and yet it remains highly beneficial because of the desire to have fewer ports. It’s all about robotic articulation delivered through a single incision that allows for the reach, necessary angles and multi-quadrant access to treat diseases in colorectal surgeries. The SPORT Surgical System has the promise to become a valuable tool for all robotic surgeons looking to do single port surgery in the future.” SEE VIDEO
Arnold Advincula, M.D., Chief of Gynecologic Specialty Surgery at Columbia University and an expert in robotic surgery, said, “After using the SPORT system, I am more convinced that single-port robotic surgery could become a reality for many patients. Previous approaches to single-incision surgery have been limiting and ineffective. The SPORT system demonstrated that it can not only address those limitations, but it may also provide some unique capabilities for enabling a variety of gynecologic surgeries through a single incision. The future of single-port robotic surgery is bright and I am excited to actively participate in this journey with Titan Medical.”
Vipul Patel, M.D., a world-renowned robotic urology surgeon from the Global Robotics Institute at Florida Hospital and the only surgeon in the world to have completed 10,000 robotic prostatectomies, said, “Although multi-port robotic prostatectomy is currently the standard of care in urology, single port robotic surgery could be the next frontier in urology and other surgical disciplines. It was exciting for me to use Titan Medical’s SPORT system at Florida Hospital Nicholson Center. The technological capabilities of the SPORT system are very encouraging and the early success in establishing feasibility is an important step in the right direction.”
William Burke, M.D., a gynecologic oncologist at Stony Brook University Hospital with extensive robotic surgery experience, commented, “Having completed thousands of multi-port robotic surgeries over several years of practice, I was pleased with the capabilities of the SPORT system that eased my transition from a multi-port approach to single-port robotic surgery. The workspace, access and ease of use while maintaining critical multi-port robotic features such as multi-articulated instruments and high-definition 3D visualization through a single incision, are important factors in transitioning from multi-port to single-port robotic surgery. I must say that the SPORT system, with its sophistication, makes a highly compelling case for single-port robotic surgery.”
Lee Swanstrom, MD, FACS, Chief Innovation Officer of IHU Strasbourg, said, “I was pleased with my first experience with the SPORT system for applications in abdominal procedures. There are many patients undergoing general surgical procedures who could greatly benefit from a reduced number of incisions. Single-port robotic surgery can be a truly enabling solution for patients and surgeons alike, and it is exciting to see that the SPORT system takes us much closer to that possibility.”
Jelle Ruurda, MD, a gastrointestinal and oncologic surgeon at University Medical Center Utrecht, who has several years of robotic surgery experience, commented, “Many oncologic general surgery procedures require specimen retrieval at the end of the procedure. These procedures are natural applications for single-port robotic surgery. My first operation of the SPORT system in a preclinical environment was very exciting, and the system shows great promise for future clinical use. I look forward to the opportunity to work together with Titan Medical to evolve a single-port robotic surgery option for my oncology patients. Based on this first experience, I am confident that single-port robotic surgery has a bright future”.
Eric Barret, MD, a world-renowned robotic urologic surgeon at Institut Mutualiste Montsouris, said, “Having performed many single-incision robotic surgeries with flexible, non-wristed and crossed-over instruments, my first experience with the SPORT system was exceptional. The SPORT system addresses many limitations of previous laparoscopic and robotic single-incision surgery approaches, and holds significant promise for meaningful use in urologic applications.”
The SPORT Surgical System is a versatile single incision advanced robotic surgical system that features state-of the-art multi-articulated instruments with single-use replaceable tips, 3D high definition visualization on a flat-screen monitor, ergonomic open workstation and a single-arm mobile patient cart for ease of set up while enabling broad applications of single and multi-quadrant surgeries previously not possible with current robotic solutions.
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2019. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation. http://www.titanmedicalinc.com/
Interim President & CEO
In his over 10 years at Zephyr, Mr. Cataford was able to grow the team to over 65 people, clear class II medical devices through both 510 (k) and De Novo FDA approval paths and build a 13485: 2016 certified manufacturing facility. Zephyr successfully closed on two joint ventures with established dental technology companies raising over $20 million from a combination of strategic and private investors. He brings significant high technology and medical device company experience and is a key contributor to strategy, M&A, corporate finance, governance, team building and empowerment and scale. Over the last 25 years, Mr. Cataford has also served as independent corporate director on a number of TSX, TSXV and NASDAQ company boards including: Sierra Wireless, Inc., Trakopolis IoT Corp., SemiBioSys Genetics Inc., and AGJunction Inc. Mr. Cataford has a Bachelor of Science degree in Mechanical Engineering from Queen’s University, an MBA specializing in Finance and International Strategy from Schulich School of Business at York University, and is a graduate of the Institute of Corporate Directors – Directors College, Rotman School of Business at the University of Toronto.
Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.
Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.
Dr. Boyd is a Professor of Surgery and Director of Robotics and Biosurgery at the University of California Davis. He is Head of Adult Cardiac Surgery and Surgical Director of the Transcatheter Valve Program. He is recognized for his pioneering work in cardiothoracic surgery and for his use of robotic-assisted surgical systems. He specializes in minimally invasive cardiac and robotic-assisted heart surgery. Dr. Boyd completed the world’s first closed-chest, beating-heart coronary artery bypass surgery using a robotic system in 1999. Prior to his appointment as a professor of surgery at UC Davis Health System, Dr. Boyd served as chair of the Department of Cardiothoracic Surgery at the Cleveland Clinic in Florida. As the author of more than 70 peer-reviewed, journal articles, Dr. Boyd’s research interests include cardiac tissue regeneration using extracellular matrix/stem cells, new techniques for robot-assisted minimally invasive coronary artery revascularization, valve surgery and tele-surgery. He is a graduate of Carleton University in Ottawa, Canada and obtained his medical degree from the University of Ottawa, Canada.
Dr. Litwin trained in General Surgery at the University of Saskatchewan, and completed a hepatobiliary fellowship at the University of Toronto. He was an early pioneer in laparoscopic surgery, having performed the first laparoscopic cholecystectomy in Western Canada in 1990 and the first laparoscopic colectomy in Canada in 1991. He was a leader in educating a large number of surgeons across Canada in basic and advanced laparoscopic techniques. During the early advent of minimally invasive surgery, he innovated new laparoscopic approaches to the spine and aorta, and he participated in the development of HandPortTM, a hand assist device for laparoscopic surgery. In 1993, Dr. Litwin became the Director of Minimally Invasive Surgery at the University of Toronto. In 1997, he moved to the University of Massachusetts as Chief of Minimally Invasive Surgery. Since 2004, he has been Chairman of Surgery at the University of Massachusetts Medical School and UMass Memorial Medical Center, one of the largest Academic Health Sciences Centers in Massachusetts. There, he continues to practice minimally invasive surgery of the abdomen in addition to his administrative role.
Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.
Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |